Q-omics provides the consensus-scored HADHB profile across patient tissues and cancer cell-line models. HADHB expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HADHB is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, HADHB RNA expression shows 19,515 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where HADHB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HADHB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HADHB survival associations across molecular data types. HADHB RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HADHB RNA expression–survival associations across cancer types. High HADHB expression shows unfavorable associations in UVM, ACC, HNSC and MESO, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HADHB RNA expression.
This table summarizes HADHB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HADHB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HADHB shows lower tumor expression in COAD, KICH, KIRP, THCA, READ and KIRC. The COAD box plot shows higher HADHB RNA expression in normal versus tumor tissue (log2 FC = −0.895, t-test p < 0.001).
This table shows molecular features associated with HADHB in patient tissues and cancer cell lines. In patient samples, HADHB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HADHB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
